Notice on Voluntary Disclosure of HY-2003 Pharmaceutical Clinical Trial Application Acceptance Notice
Notice of voluntary disclosure of concentrated sodium valproate solution for injection to obtain marketing approval in Ireland
Notice of voluntary disclosure that proxafil injections, injectable azacitidine, and injectable cetipa have obtained marketing licenses in Israel, Egypt, and Northern Ireland, respectively
Notice on Voluntary Disclosure of HYP-6589 Tablets Acceptance Notice of Application for Drug Clinical Trials
Board Secretary Work System
Announcement on voluntary disclosure of Zoledronic acid injection obtaining marketing authorization in the Netherlands.
Announcement of voluntarily disclosing the approval of Azacitidine for injection and Benidipine hydrochloride injection in obtaining Uzbekistan market license.
Announcement Regarding Directors and Senior Management Receving Notices of Filing
Announcement of voluntary disclosure of the marketing authorizations obtained for Oxaliplatin Injection and Zoledronic Acid Injection in Costa Rica and Ireland.
Announcement of voluntarily disclosing approvals for injection use of Voriconazole and Sodium Valproate Injection Concentrate in Portugal and Germany.
Announcement of voluntary disclosure of regulatory approval for injection use of Setipar in Portugal.
Announcement on the completion of some of the raised funds investment projects for the initial public offering of stocks.
Announcement regarding the completion of the conversion of certain special voting shares into ordinary shares.
Voluntary disclosure of the announcement of the approval of injection of Voriconazole and Zoledronic Acid Injection in Ireland and Portugal, respectively.
Announcement about the voluntary disclosure of the approvals for two products, Docetaxel Injection, and others, to be in the market of Turkmenistan.
Announcement on the conversion of part of special voting share to ordinary share.
Action plan for "Improving Quality, Increasing Efficiency, and Returning to Benefits" for the year 2024.
Announcement about voluntary disclosure of the acceptance notice of drug clinical trial application for HY07121 injection
Announcement Regarding Voluntary Disclosure and Withdrawal of Pharmaceutical Application for Registration.
Announcement on voluntary disclosure of three products, including docetaxel injection, obtaining market approval in Uzbekistan.
No Data
No Data